Objective:

To develop a self-driving bioprocessing platform that optimizes monoclonal antibody production using machine learning and automated bioreactors.

Key Findings:

• The platform autonomously operated for 20 days during a 27-day monoclonal antibody production run.
• It successfully met performance targets, increasing viable cell volume and maintaining cell viability.
• The system demonstrated knowledge transfer between experiments, potentially reducing the number of experiments needed for optimization.

Interpretation:

The integration of predictive models and adaptive control in bioprocessing platforms can significantly enhance decision-making and reduce manual intervention, addressing the challenges of time and resource intensity in biopharmaceutical development.

Limitations:

• The study primarily serves as a proof of concept and may require further validation in diverse bioprocess scenarios.
• The effectiveness of the system in different cell lines and production scales needs additional exploration.

Conclusion:

This innovative approach could streamline biopharmaceutical development, making it more efficient and responsive to real-time data, thereby meeting industry demands for faster and more robust processes.